Abstract: Objective: To evaluate the effect of parameter setting with sacral neuromodulation in different diseases. Method: A retrospective analysis was performed on the information of patients who received the Phase Ⅱ permanent sacral neuromodulation from March 2016 to December 2018 in the south hospital of Renji, affiliated to Shanghai Jiao Tong University School of Medicine. A total of 117 patients were enrolled in this study, which were divided into four groups according to the type of disease: 9 patients in the overactive bladder group, 31 patients in the pelvic pain group, 66 patients in the neurogenic bladder group, and 11 patients with dysuria group. The age, gender, electrode placement, stimulation mode, voltage, pulse width, frequency and other parameters of the patients in the four groups were statistically analyzed. Result: The age of patients in the four groups were (51.11±14.09) years old, (57.62±14.13) years old, (53.36±22.42) years old and (55.09±19.42) years old, respectively. There were 1 male and 8 females in the overactive bladder group. The pelvic pain group included 13 males and 18 females. Neurogenic bladder group included 34 males and 32 females. The dysuria group included 7 males and 4 females. The voltage of the four groups were (1.91±1.56) V, (1.22±0.54) V, (1.47±0.81) V and (1.38±0.76) V, respectively (P＞0.05). After implantation, there was no statistically significant difference among the post-implantation overactive bladder group (262.50±81.37) μs, the pelvic pain group (270.00±68.68) μs, the neurogenic bladder group (286.15±65.83) μs and the dysuria group (265.00±77.78) μs. The frequencies of the four groups were (11.87±5.41) Hz, (19.20±13.10) Hz, (29.79±9.51) Hz, (20.50±10.11) Hz, respectively (P＜0.01).Conclusion: Combined with the analysis of the results, the startup frequency of neurogenic bladder patients was significantly higher than that of the other overactive bladder group, pelvic pain group and the dysuria group. There was no significant difference in voltage or pulse width among the four groups. Therefore, in the future, the frequency of neurogenic bladder patients can be appropriately increased in sacral neuromodulation test, so that patients can achieve better efficacy.